Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.38 |
| ▸ | TEK | Q02763 | 8/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409634 | 1.00 | KDR (0.38) | KDRTEKSRCGSK3BMEN1 | |
| SCHEMBL2179067 | 0.90 | KDR (0.40) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL12409660 | 0.90 | KDR (0.40) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL2181263 | 0.86 | MEN1 (0.36) | KDRTEKSRCGSK3BMEN1 | |
| SCHEMBL12409608 | 0.86 | MEN1 (0.36) | KDRTEKSRCGSK3BMEN1 | |
| SCHEMBL2178773 | 0.85 | TEK (0.38) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL6750681 | 0.84 | KDM4E (0.49) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL6750654 | 0.84 | KDM4E (0.49) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL4527244 | 0.84 | KDM4E (0.49) | KDRTEKGSK3BMEN1KMT2A | |
| SCHEMBL12409633 | 0.83 | MEN1 (0.37) | KDRTEKGSK3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2158206-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | KDR 1007/4885TEK 374/4885SRC 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.